Eagle Pharmaceuticals Inc (EGRX) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eagle Pharmaceuticals, Inc. is on the clock to file its overdue quarterly report after receiving a delinquency notice from Nasdaq for not complying with listing rules. They’ve been granted a 180-day extension until May 13, 2024, to submit their financials and avoid delisting. The company’s future on the stock market hangs in the balance as they work to meet the deadline and maintain their listing status.
For further insights into EGRX stock, check out TipRanks’ Stock Analysis page.